This study represents one of the most comprehensive molecular analyses performed on fibrolamellar carcinoma (FLC). Using more than 1,400 tumor and normal liver samples, including 220 FLC and FLC‑like tumors, the research team used techniques including RNA sequencing, DNA sequencing, proteomics, methylation analysis, and spatial single‑cell mapping to better understand FLC at the molecular level. Their findings define FLC as a single, unified disease driven by overactive Protein Kinase A (PKA)—regardless of the specific genetic mechanism involved.
Key Findings:
- FLC is a single disease with one core driver: too much PKA activity. Regardless of the cause, the classic DNAJB1‑PRKACA fusion, rarer fusions (e.g., ATP1B1::PRKACA), or mutations that remove PKA’s regulatory brakes (e.g., PRKAR1A loss), the downstream biology was identical. All of these tumors shared the same gene‑expression pattern, confirming that elevated PKA activity is the root cause of FLC.
- A “FLC signature” of 693 genes was created. The team identified a robust gene-expression signature that distinguishes FLC tumors from normal liver tissue; works across different sequencing platforms, and sample types; and distinguishes FLC from hepatocellular carcinoma, cholangiocarcinoma, and hepatoblastoma.
- Primary tumors and metastases are almost identical. In their analysis of a wide range of samples, the team determined that metastatic FLC tumors differ from their matching primary tumors in only 0.6% of genes—a very small shift. This finding implies that metastasis in FLC is not driven by new mutations or major evolution of the cancer. It also confirms that treatments that target the primary tumor biology should also be effective against metastases.
- Spatial single‑cell mapping reveals the tumor ecosystem. The team used state-of-the-art spatial transcriptomics techniques to map gene activity within individual cells in FLC tumors. They concluded that fibrolamellar’s collagen bands arise mainly from stromal cells, not cancer cells, and that FLC tumors show low immune cell infiltration (especially macrophages and CD4 T‑cells). They also determined that immune checkpoint markers (e.g., PD‑1/PD‑L1) are low. This could explain why checkpoint inhibitors have not shown benefit in most FLC patients.
- FLC models used for drug testing were validated. Through their analysis, the team determined that patient‑derived xenografts (PDX), organoids, and engineered hepatocytes closely match human tumors at the molecular level. This strengthens confidence that currently used experimental platforms are appropriate for therapy development.
Implications of the study:
This study provides a clear understanding of what FLC is, and what it is not. It establishes a unified biological definition of the disease, highlights PKA signaling as a central therapeutic target, and offers a validated gene signature that could improve diagnosis, classification, and research reproducibility.